Protagen AG and MicroDiscovery GmbH cooperate in biomarker development
(PresseBox) - Dortmund based Protagen AG, a specialist in in-vitro diagnostics and GMP-conform protein analytics and MicroDiscovery GmbH, a bioinformatics company based in Berlin, have started a cooperation to identify and validate biomarkers for medically relevant diseases.
"Our proprietary technology platform UNIarray® and MicroDiscovery's certified software solutions for the analysis of complex marker panels complement each other perfectly," states Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics of Protagen AG and adds: "The cooperation strengthens our position in biomarker development and supports the efficient development of marketable products."
Dr. Arif Malik, CEO of MicroDiscovery GmbH, confirms: "Our experience in analyzing clinical studies for multiplex assays and array data perfectly fits with Protagen's established screening platform. This illustrates the value of MicroDiscovery's bioinformatics methods and software solutions for the development of new diagnostics."
About MicroDiscovery GmbH
MicroDiscovery is a leading provider of innovative and certified software solutions for diagnostics, individualized medicine and molecular biological research. The Berlin-based company was founded in the year 2000 and has managed to attract many renowned customers due to its high competence in realizing custom software solutions. This know-how is combined with complementary services ranging from biostatistical data analysis and algorithm development to bioinformatics assistance for complex research projects.
Protagen AG (www.protagen.de), located in Dortmund, Germany, is an international leading specialist in the fields of in-vitro diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNIarray®, a technology platform for the development of novel serum based diagnostics, as well as UNIchip®, a versatile product family of protein microarrays for faster development of antibodies.
Protagen AG (www.protagen.de), located in Dortmund, Germany, is an international leading specialist in the fields of in-vitro diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNIarray®, a technology platform for the development of novel serum based diagnostics, as well as UNIchip®, a versatile product family of protein microarrays for faster development of antibodies.
" alt="ERA Announces Canada’s First Ever Public-Private Partnership Involving Carbon Finance and Conservation on Over 750 Hectares of Ecologically Sensitive Lands on Denman Island">
" alt="Bass Metals Ltd.: Operations Update and New Production Growth Initiative">
Datum: 13.10.2010 - 16:16 Uhr
Sprache: Deutsch
News-ID 25787
Anzahl Zeichen: 0
contact information:
Town:
Dortmund/Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 416 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Protagen AG and MicroDiscovery GmbH cooperate in biomarker development"
steht unter der journalistisch-redaktionellen Verantwortung von
Protagen AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
